Neuromyelitis optica (NMO) is a severe autoimmune disease in which the immune system attacks the optic nerves and spinal cord, causing vision loss, paralysis, and other neurological problems. Once thought to be a form of multiple sclerosis, NMO is now recognized as a completely distinct condition with different biology, different imaging patterns, and different treatments. An estimated 22,000 Americans were living with NMO spectrum disorder (NMOSD) in 2022, making it relatively rare but serious enough that misdiagnosis can lead to the wrong treatment and worse outcomes.
How NMO Damages the Nervous System
In most people with NMO, the immune system produces an antibody called AQP4-IgG that targets a water-regulating protein found on the surface of astrocytes, the support cells that help maintain the protective barrier between the bloodstream and the brain. These astrocytes are especially concentrated in the optic nerves, spinal cord, and certain parts of the brainstem. When AQP4 antibodies bind to these cells, they trigger inflammation that damages and destroys the astrocytes, essentially attacking the “gatekeepers” that normally keep harmful immune activity out of the central nervous system.
Once those gatekeepers are compromised, other immune cells flood into the area and cause further destruction. This is why NMO attacks tend to be more severe and more destructive than what’s seen in MS. The areas where the blood-brain barrier is naturally more permeable, such as a region at the base of the brainstem called the area postrema, are particularly vulnerable to early damage.
Symptoms of an NMO Attack
NMO symptoms depend on which part of the nervous system is under attack, but they almost always involve the eyes, the spinal cord, or both.
When inflammation hits the optic nerve (optic neuritis), you may experience blurred or lost vision in one or both eyes, eye pain, and an inability to see color. When it strikes the spinal cord (transverse myelitis), symptoms include stiffness, weakness, or numbness in the legs and sometimes the arms, shooting pain in the neck or back, tingling sensations, and difficulty controlling bladder or bowel function. Some people also develop persistent, uncontrollable hiccups and nausea, which signals that the area postrema in the brainstem is involved.
These symptoms arrive suddenly and are often severe. NMO follows a relapsing pattern in the vast majority of cases: symptoms improve partially or fully, then flare again weeks, months, or years later. Up to 90% of people who test positive for AQP4 antibodies will experience relapses over the course of their disease. Each relapse matters. Research from phase 3 clinical trials has shown that even a single relapse causes measurable, permanent worsening of disability and quality of life, with effects still detectable four months later. Over time, repeated attacks can lead to total blindness, the inability to walk without assistance, or complete paralysis.
How NMO Differs From Multiple Sclerosis
NMO and MS can look similar at first glance since both cause inflammation in the brain and spinal cord. But they behave differently in almost every important way. NMO attacks tend to be more sudden and more severe. On spinal MRI, NMO typically produces long, continuous lesions stretching across three or more vertebral segments, centered in the middle of the cord. MS lesions are usually short, patchy, and located near the outer edge of the cord, rarely spanning more than one vertebral segment.
Brain MRI findings also diverge. Most NMO patients have few or no typical white matter lesions on brain scans, while MS almost always shows scattered brain lesions. Spinal fluid analysis can offer another clue: NMO patients frequently have elevated white blood cell counts in their cerebrospinal fluid, sometimes including neutrophils, which is unusual in MS. The distinction matters practically because some standard MS therapies, including interferon beta, can actually worsen NMO and trigger more frequent relapses.
Who Gets NMO
NMO affects women far more than men, with a ratio of roughly 3 to 5 women for every man diagnosed. In the United States, the overall prevalence is about 6.9 per 100,000 people, but it varies significantly by race. Black Americans have the highest prevalence at about 13 per 100,000, followed by Asian Americans at 9.4 per 100,000 and white Americans at 5.6 per 100,000. Among women specifically, Black and Asian women are roughly 2 to 3 times more likely to have NMOSD than white women. Interestingly, in men, the prevalence does not differ significantly by race.
How NMO Is Diagnosed
Diagnosis relies on a combination of clinical symptoms, blood tests for AQP4 antibodies, and MRI imaging. International consensus criteria established in 2015 define six core features that point toward NMO, each tied to a specific region of the nervous system: the optic nerve, spinal cord, area postrema, other brainstem structures, the hypothalamus region, and the cerebrum.
If AQP4 antibodies are detected in your blood, only one of these six clinical features needs to be present for diagnosis. If the antibody test comes back negative or is unavailable, the bar is higher: you need at least two different core features affecting different parts of the nervous system, and at least one of them must be optic neuritis, transverse myelitis with a long spinal cord lesion on MRI, or symptoms from area postrema involvement with a corresponding brainstem lesion.
On MRI, the hallmarks of NMO include spinal cord lesions spanning three or more vertebral segments, optic nerve lesions extending over more than half the nerve’s length, and bilateral optic nerve involvement. Bright, spotty-looking spinal cord lesions and distinctive cloud-like patterns of enhancement are additional imaging clues that help distinguish NMO from other conditions.
MOG Antibody Disease: A Related Condition
Not everyone with NMO-like symptoms tests positive for AQP4 antibodies. Some instead carry antibodies against a different protein called MOG. MOG antibody disease (MOGAD) produces similar attacks of optic neuritis and spinal cord inflammation but has some distinct features. It more commonly affects younger men and Caucasian populations, while AQP4-positive NMO skews toward women and non-white populations.
MOGAD tends to cause bilateral optic neuritis (affecting both eyes simultaneously) more often, occurring in about 63% of MOGAD cases compared to 25% in AQP4-positive NMO. Spinal cord involvement in MOGAD more often targets the lower end of the cord (the conus), while AQP4 disease favors the neck and upper back portions. Perhaps most importantly, MOGAD generally carries a better long-term outlook. Spinal cord lesions in MOGAD patients tend to resolve on imaging without leaving behind significant cord shrinkage, whereas about 24% of AQP4-positive patients develop visible cord atrophy over time.
Treatment for Acute Attacks
When an NMO relapse strikes, the immediate goal is to reduce inflammation as quickly as possible to limit permanent damage. The standard first step is a course of high-dose intravenous steroids, typically given over three to five days. If symptoms don’t respond, a second, higher-dose round of steroids may be tried within about two weeks. For relapses that remain resistant to steroids, plasma exchange (a procedure that filters harmful antibodies out of the blood) is the next escalation step.
Preventing Future Relapses
Because each relapse carries the risk of permanent, cumulative damage, long-term prevention is the cornerstone of NMO management. Since 2019, three medications have received FDA approval specifically for AQP4-antibody-positive NMOSD: eculizumab, inebilizumab, and satralizumab. All three work by targeting different parts of the immune system to reduce the frequency of attacks. In clinical trials, the most effective of these reduced the risk of relapse by 94%. For people living with NMO, staying on preventive therapy is one of the most important factors in preserving vision, mobility, and independence over the long term.